Please assess the completion status of the following clinical trial:

Trial Title: Recall by Genotype: Neuropeptide Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No prescription medications that could interfere with hypothalamic reproductive function~* No illicit drug use~* No excessive alcohol consumption (more than 10 drinks/week)~* No history of an allergic medication reaction requiring emergency medical care~* Normal blood pressure reading (systolic blood pressure \< 140 mm Hg, diastolic \< 90 mm Hg)~* White blood cell, platelet counts, prolactin, and thyroid-stimulating hormone (TSH) between 90% of the lower limit and 110% of the upper limit of the reference range~* Normal hemoglobin~* Blood urea nitrogen (BUN), creatinine not elevated~* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) within 3 times upper limit of normal~* Enrolled in the Partners HealthCare Biobank and genotypically characterized~* For women~  * No oral contraceptives for at least 1 month~ * No contraceptive implants for at least 3 months~ * Not breastfeeding and not pregnant~ * Negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of screening (additional urine pregnancy test will be conducted prior to drug administration)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- kisspeptin, GnRH (Type: EXPERIMENTAL): IV administration of kisspeptin 112-121; one bolus. IV administration of GnRH; one bolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).